



**RADIOMOLECULAR  
PRECISION  
ONCOLOGY**  
FOR PATIENTS WORLDWIDE

THE ICPO FOUNDATION.

# ICPO THERANOSTICS VIRTUAL SUMMIT 2026 NOVEMBER 12 & 13, 2026

(VERSION APRIL 2026)

## CHAIRS



**Prof. Richard P.  
Baum**



**Prof. Frederik L.  
Giesel**



**Prof. Rudolf A.  
Werner**

## World-class programme:

Strong on multidisciplinary exchanges and patient focus covering 5 themes:

- Rising stars in Theranostics - Beyond PSMA and FAP
- Growing space of Alphas - Outlook on untapped potential
- Clinical trials planning - Navigate from hurdles to outcomes
- Leveraging AI in Theranostics - Advancing clinical practice globally
- Recommendations to grow patient access to Theranostics innovation over the next 5 years

## MODERATORS



**Odile Jaume  
CEO**



**Susanne Simon  
Head of Communications**



**Pre-Register here:  
[www.icpo.foundation](http://www.icpo.foundation)**



<b>Day 1 - Nov 12, 2026 (CET)</b>	<b>Adopting new radiopharmaceuticals at your Theranostics center</b>
2:00 - 2:15 pm	<b>Welcome - Udo J. Vetter &amp; Odile Jaume</b> <b>Programme overview by Chairs - Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner</b> Keynote introduction – Susanne Simon
2:15 - 2:35 pm	<b>KEYNOTE: From Imaging to Cure: Theranostics as a Core Pillar in Today's Oncology Toolbox – Michael Hofman</b>
2:35 - 3:25 pm	<b>SESSION I: Outlook into Next Gen emitters</b> - Reminiscence of Y90 DOTATOC for NET – Richard P. Baum - Selection of optimal radionuclide: Efficacy and safety of Tb161 versus Lu177 – Cristina Mueller - Clinical potential of Tb161 for radioligand therapy – Damian Wild
3:25 - 4:25 pm	<b>SESSION II: Clinical trends in Alpha corner</b> - Ac225 insights in latest trials – Mike Sathekge - Latest clinical advances in Astatine (At211): Tadashi Watabe - Novel development and dosing strategies for alpha therapies, ADV001 (Pb212) experience – Anna Karmann - Pb212 beyond prostate cancer – Michael Schultz
4.30 - 4:55 pm	<b>PANEL 1: Alpha only approach: Potential &amp; effectiveness? Benchmark with combination therapies?</b> Moderators: Frederik L. Giesel and Rudolf A. Werner
4:55 - 5:05 pm	<b>BREAK</b>
5:05 - 5:55 pm	<b>SESSION III: Sunrise of FAP &amp; other compounds on the horizon</b> - FAP-based radiotheranostics for the treatment of diverse adenocarcinomas and sarcomas – Elisabetta Perrone - 3rd Generation of PSMA – Steven Rowe - Novel targets incl. CAIX, PL1 and others – Masato Murakami
5:55 - 6:40 pm	<b>SESSION IV: Will “big” or “small” shape the future? What space for pre-targeting?</b> - Perspective from radiopharmaceutical innovation – Jens Cardinale - Perspective from clinical radiochemistry – Jason Lewis - Perspective from translational nuclear medicine – Susanne Lütje
6:45 - 7:10 pm	<b>PANEL 2: Is FAP revolutionary in terms of patient outcomes? Will it become the new gold standard for all Theranostics centers?</b> Moderators: Richard. P. Baum and Frederik L. Giesel
7:10 - 7:15 pm	<b>Wrap up and Closing of Day 1</b> <b>Day 1 Impressions from Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner</b> Closing - Odile Jaume & Susanne Simon

# ICPO THERANOSTICS VIRTUAL SUMMIT 2026

NOVEMBER 12 & 13, 2026

**GROWING PATIENT ACCESS: ADOPTING NEW RADIOPHARMACEUTICALS  
THERAPIES AND PLANNING FOR CLINICAL TRIALS**



<p><b>Day 2 – Nov 13, 2026 (CET)</b></p>	<p><b>Planning and navigating clinical trials at your Theranostics center</b></p>
<p>10:00-10:05 am</p>	<p><b>Welcome - Odile Jaume</b>  <b>Programme overview by Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner</b>                  Keynote introduction – Susanne Simon</p>
<p>10:05-10:25 am</p>	<p><b>KEYNOTE: Future outlook into radiotheranostics - Ken Herrmann</b></p>
<p>10:25-11:15 am</p>	<p><b>SESSION V: Planning your clinical trial</b>                  - Current and future design of theranostics clinical trials – Igor Rakovic                  - Structuring &amp; managing trial data – Sam Vohra                  - Listening to patients advocates on clinical trials – Erik Briers</p>
<p>11:15-12:00 am</p>	<p><b>SESSION VI: Navigating trial design involving novel approaches</b>                  - First use of Re188-PSMA, as Tc99m-PSMA companion: Mike Sathekge                  - uPAR-targeted PET imaging (muPA) tracers in oncology research – Andreas Kjaer                  - Role of Genomics &amp; Transcriptomics or when in vitro meets in vivo – Ralph Wirtz</p>
<p>12:00-12:25 am</p>	<p><b>PANEL 3: Lessons learned for a Theranostics center head: Success factors and attention points</b>                  Moderators: Richard. P. Baum and Rudolf A. Werner</p>
<p>12:25-12:35 am</p>	<p><b>BREAK</b></p>
<p>12:35-1:25 pm</p>	<p><b>SESSION VII: How to reach and select patients for your trials?</b>                  - Theranostics patient selection at large volume cancer center – Désirée Deandreis                  - Challenges and opportunities in patient recruitment for Theranostics                  in emerging research centers – Cecilia Carreras                  - Leveraging Ancora.ai radiopharmaceuticals trial finder – Danielle Ralic</p>
<p>1:25-2:15 pm</p>	<p><b>SESSION VIII: Leveraging AI in Theranostics at your center</b>                  - Leveraging AI to advance clinical Theranostics globally – Johannes Tran-Gia                  - Empowering AI in clinical trials - Vikas Prasad                  - ARCHE: An AI-driven Curation and Harmonization Engine for Structuring                  Multimodal Theranostics Data – Lalith Sundar</p>
<p>2:15-2:40 pm</p>	<p><b>PANEL 4 / FINAL ROUND TABLE: Essential recommendations to grow patient access to radiotheranostics innovation over the next 5 years?</b>                  Moderators: Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner</p>
<p>2:40-3:00 pm</p>	<p><b>Wrap up and closing of ICPO Summit 2026</b>  <b>Wrap up by Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner</b>                  Closing by Odile Jaume and Susanne Simon</p>